K Kozaki
Tokyo Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by K Kozaki.
Clinical Pharmacology & Therapeutics | 1997
Toshihiko Hirano; Kitaro Oka; Hironori Takeuchi; K Kozaki; Naoto Matsuno; T Nagao; Masami Kozaki; Makiko Ichikawa; Masaharu Yoshida; Yoshinori Umezawa; Masako Hirata; Tsunao Oh-I; Michiyuki Koga
In organ transplantation, patients with peripheral blood mononuclear cells (PBMCs) that exhibit resistance to cyclosporine (INN, ciclosporin) or glucocorticoids in vitro are refractory to therapy based on these drugs in vivo. However, detection or distribution of the resistant patients with immunologic disorders remains to be documented.
Immunopharmacology | 1997
Atsushi Horigome; Toshihiko Hirano; Kitaro Oka; Hironori Takeuchi; Etsuo Sakurai; K Kozaki; Naoto Matsuno; T Nagao; Masami Kozaki
Induction of apoptosis by immunosuppressive agents such as glucocorticoids (GCs) and cyclosporine (CsA) in cultured lymphoid cells has been suggested. However, there are few studies which demonstrate the induction of apoptosis by these agents in the activation process of human peripheral blood mononuclear cells (PBMCs). Here we show that potent immunosuppressive GCs and CsA induce apoptosis in concanavalin A (con A)-activated human PBMCs. In this study, GCs and CsA suppressed human PBMC-blastogenesis when activated by con A in a dose-dependent manner, where healthy PBMCs treated with > 100 ng/ml of each immunosuppressive agent exhibited a DNA-ladder structure in electrophoretic analysis. In three chronic renal failure (CRF) patients, dose-dependency of the PBMC-apoptosis induction was confirmed by our quantification of fragmented DNA using ELISA. Furthermore, the enrichment of DNA fragmentation was significantly associated with the rate of PBMC-blastogenesis when treated with GCs or CsA (r = -0.466, P < 0.01). These results suggested that suppression of the mitogen-induced PBMC-blastogenesis by the immunosuppressive agents should be correlated with the induction of apoptosis.
Clinical Transplantation | 2000
Toshihiko Hirano; Kitaro Oka; Hironori Takeuchi; Etsuo Sakurai; K Kozaki; Naoto Matsuno; Masami Kozaki; T Nagao
A large difference in immunosuppressive potency between methylprednisolone and prednisolone has been suggested in vitro. However, the selection of the best glucocorticoid for renal transplantation has been seldom considered so far. Thus, the present study was undertaken to compare therapeutic efficacy between prednisolone and methylprednisolone in renal transplantation. We studied 42 renal transplant recipients who were operated on between 1990 and 1994. The patients were divided into two treatment groups: a methylprednisolone/cyclosporine group (n=19) and a prednisolone/cyclosporine group (n=23). Clinical outcome and drug side effects were compared retrospectively between the treatment groups 24–84 months after transplantation. The overall graft survival time in patients treated with methylprednisolone/cyclosporine was superior to that in patients treated with prednisolone/cyclosporine (p<0.05). Among the recipients from cadaver donors, 5/16 (31.3%) treated with prednisolone required nephrectomy, whereas none of the 10 patients treated with methylprednisolone received nephrectomy (p<0.01). An examination of the recipients from living related donors revealed that serum creatinine levels 24–36 months after operation were significantly lower in the methylprednisolone group (p<0.05). Cyclosporine trough levels and glucocorticoid side effects were similar between the treatment groups. The results raised the possibility that methylprednisolone is superior to prednisolone when combined with cyclosporine for maintenance immunosuppressive therapy in renal transplantation.
Annals of Nuclear Medicine | 2001
Kiyoshi Koizumi; Hideo Kakiuchi; Toru Saguchi; Shingo Inoue; Shuichiro Fuse; Etsuko Kawakami; Akira Yamazaki; K Kozaki; T Nagao
We proposed a simple parameter, the kidney-to-aorta ratio (KAR), for evaluation of renal transplant perfusion. KAR was calculated from the peak counts of the kidney and the aorta. The calculated values were compared with the visual interpretation of the radionuclide first-pass flow study, percent renal uptake (%RU), and tubular extraction rate (TER) by Bubeck’s one point sampling method in 37 studies. KAR correlated well with the visual interpretation of the flow study and the other quantitative parameters. Representative cases, which showed the usefulness of KAR for the objective assessment of the perfusion status of renal transplants, were presented. In conclusion, KAR is a simple and practically useful parameter for objective evaluation and follow-up of renal transplant perfusion.
Transplantation Proceedings | 2000
H. Iwamoto; Naoto Matsuno; Y Narumi; M Uchiyama; K Kozaki; H Degawa; K. Hama; K Kikuchi; H Takeuchi; Masami Kozaki; T Nagao
Transplantation Proceedings | 2000
Naoto Matsuno; K Kozaki; H Degawa; Y Narumi; N Suzuki; K Kikuchi; M Uchiyama; K Kubota; Etsuo Sakurai; Masami Kozaki; T Nagao
Transplantation Proceedings | 2001
M Uchiyama; Naoto Matsuno; K. Hama; H. Iwamoto; Y Narumi; K Kikuchi; H Degawa; K Kozaki; Kazuo Kubota; H Takeuchi; Etsuo Sakurai; N Asuwa; S Masuda Toshihiko Hirano; T Nagao
Transplantation Proceedings | 2000
K Kozaki; Etsuo Sakurai; M Uchiyama; Naoto Matsuno; Masami Kozaki; T Nagao
Transplantation Proceedings | 2002
H. Iwamoto; K Kozaki; N Nakamura; K. Hama; K Narumi; Naoto Matsuno; K. Kuzuoka; Shinichiro Taira; Y. Kihara; M Uchiyama; H Takeuchi; T Nagao
Transplantation Proceedings | 1999
Naoto Matsuno; K Kozaki; H Degawa; Y Narumi; N Suzuki; K Kikuchi; M Uchiyama; Etsuo Sakurai; Masami Kozaki; T Nagao